| CAS NO: | 1356929-49-1 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| Cas No. | 1356929-49-1 |
| Canonical SMILES | [2H]C1=C([2H])C([2H])=C([2H])C([2H])=C1CC[C@@H](C(OCC)=O)N[C@@H](C)C(N2CC3=CC(OC)=C(OC)C=C3C[C@H]2C(O)=O)=O |
| 分子式 | C27H29D5N2O7 |
| 分子量 | 503.6 |
| 溶解度 | DMSO: soluble,Methanol: soluble |
| 储存条件 | -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Moexipril-d5intended for use as an internal standard for the quantification of moexipril by GC- or LC-MS. Moexipril is a prodrug form of the angiotensin converting enzyme (ACE) inhibitor moexiprilat.1It is converted to moexiprilatin vivoby side chain ester hydrolysis.2Moexipril inhibits ACE in a cell-free assay (IC50= 2.7 µM for the rabbit enzyme). It also inhibits phosphodiesterase 4 (IC50s = 38, 160, and 230 µM for PDE4B2, PDE4A5 and PDE4D5, respectively).2Moexipril (0.1-30 mg/kg per day) reduces blood pressure in spontaneously hypertensive rats.1It also reduces infarct volume in a rat model of focal cerebral ischemia when used at a concentration of 0.01 mg/kg.3 1.Edling, O., Bao, G., Feelisch, M., et al.Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: Pharmacological characterization and comparison with enalaprilJ. Pharmacol. Exp. Ther.275(2)854-863(1995) 2.Cameron, R.T., Coleman, R.G., Day, J.P., et al.Chemical informatics uncovers a new role for moexipril as a novel inhibitor of cAMP phosphodiesterase-4 (PDE4)Biochem. Pharmacol.85(9)1297-1305(2013) 3.Ravati, A., Junker, V., Kouklei, M., et al.Enalapril and moexipril protect from free radical-induced neuronal damage in vitro and reduce ischemic brain injury in mice and ratsEur. J. Pharmacol.373(1)21-33(1999) |
m.cnreagent.com